Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia

Epistaxis Clinical Trial

Official title:

An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03850730
• Other study ID #: HT3
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: July 1, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: September 2022
• Source: Cure HHT
• Contact: Nicole Schaefer
• Phone: 410-357-9932
• Email: nicole.schaefer[@]curehht.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Investigators will test the value of very low dose Pazopanib administered to patients with hereditary hemorrhagic telangiectasia for the reduction in the severity of nose bleeds in those with frequent and long duration bleeding episodes.

Description:

Based on frequency and nose bleed duration, a non-randomized, single arm, open label study of 30 hereditary hemorrhagic telangiectasia patients will be treated with very low dose Pazopanib [25mg-similar] for between 16 and 24 weeks.. The primary endpoint is a reduction in bleeding duration of 50% or more, along with multiple secondary related endpoints, including bleed frequency, blood counts and quality of life; as compared to 6-12 weeks of baseline characteristics. If after the first 8 weeks of therapy benefit is suboptimal, dose advance to 50mg-similar daily can be considered.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: December 31, 2025
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• a definite diagnosis of hereditary hemorrhagic telangiectasia defined as having at least 3 of the following criteria:

• Spontaneous and recurrent epistaxis.

• Multiple telangiectasias at characteristic sites: lips, oral cavity, fingers, nose.

• Visceral lesions: GI telangiectasia, pulmonary, hepatic, cerebral or spinal AVMs.

• A first degree relative with hereditary hemorrhagic telangiectasia according to these criteria.

• OR a gene sequencing diagnosis of hereditary hemorrhagic telangiectasia

2. Epistaxis due to hereditary hemorrhagic telangiectasia at least 2x per week, for a cumulative duration of at least 25 minutes per week

3. Epistaxis is clinically stable during the 12 weeks prior to screening in the clinical judgment of the investigator (i.e. no major changes in frequency or duration of epistaxis).

4. Participant agrees not to undergo cautery of nasal telangiectasias or take any experimental therapies for hereditary hemorrhagic telangiectasia other than the study drug while participating in the study.

5. Male or female [non-child bearing potential]

Exclusion Criteria:

1. Participant has known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib that in the opinion of the investigator contradicts their participation.

2. Currently has untreated cerebral arterio-venous malformations (AVMs), cerebral arteriovenous fistulae, or cerebral cavernous malformations (CCMs) (Note: MRI scan does not need to be repeated at screening if AVMs, arterio-venous fistulas and CCMs were absent on a scan at age =18 years).

3. Currently has perfused pulmonary AVMs with feeding artery diameter >3mm.

4. Known significant bleeding sources other than nasal or gastrointestinal.

5. Systemic use of a vascular endothelial growth factor inhibitor in the past 3 months or previous enrollment in this study.

6. Active and recent onset of clinically significant diarrhea.

7. Current or recent (in the last 5 years) malignancies (except non-melanoma skin cancers)

8. Participant has had major surgery (e.g. surgical ligation of an AVM) or trauma within 28 days or had minor surgical procedures (e.g. central venous access line removal) within 7 days prior to dosing, the latter representing a recent wound, fracture or ulcer

9. Participant has a planned surgery during the period to include active treatment and 6 weeks of follow up.

10. Participant has clinically significant gastrointestinal abnormalities (other than hereditary hemorrhagic telangiectasia related vascular lesions)

11. Participant during the 6 months prior to first dose of study drug has a history of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism, untreated deep vein thrombosis (DVT), myocardial infarction, or any other thrombotic event.

12. QTc =450 msec, based on averaged QTc values of triplicate ECGs obtained over a brief recording period [The QTc is the QT interval corrected for heart rate according to either Bazett's formula (QTcB), Fridericia's formula (QTcF), or another method, machine or manual overread. The same QT correction formula must be used for each individual participant to determine eligibility for and withdrawal from the study.]

13. Hgb <6 g/dL.

14. Platelets < 100x109/L.

15. International normalized ratio (INR) >1.2x upper limit of normal and activated partial thromboplastin time (aPTT)>1.2x upper limit of normal.

16. Alanine Transaminase >2x upper limit of normal.

17. Bilirubin >1.5x upper limit of normal (isolated bilirubin >1.5x upper limit of normal is acceptable if bilirubin is fractionated and direct bilirubin <35%).

18. Participant has poorly controlled hypertension [defined as systolic blood pressure (SBP) = 140 mmHg or diastolic blood pressure (DBP) =90 mmHg. Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry [between screen and baseline]. At Screening, blood pressure must be assessed three times and the mean SBP/DBP must be <140/90 mmHg in order for a participant to be eligible for the study.]

19. Substantive renal disease (eGFR <30 mL/min/1.73m2calculated using the Cockcroft-Gault formula)

20. Echo derived left ventricular ejection fraction <30%.

21. Thyroid stimulating hormone > upper limit of normal.

22. Urine protein to creatinine ratio >0.3.

23. Neutrophil count <1500/mm3.

Related Conditions & MeSH terms

• Epistaxis
• Hereditary Hemorrhagic Telangiectasia
• Telangiectasia, Hereditary Hemorrhagic
• Telangiectasis

Intervention

Drug:
• Pazopanib
Active pharmaceutical ingredient plus excipients filled into a capsule for the lower dosing necessary in this study

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Cure HHT	University of North Carolina

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Interrogate levels of Iron stores	Ferritin serum levels [normal range 12 ug/ ml to 150ug/ml female, 300ug/ ml male]. However, above 30ug/ ml valued as relevant for proper erythropoiesis]	baseline and at on-drug study end; 16, 20 or 24 weeks depending on study duration
Other	Characterize change in left ventricular stress	NTproBNP serum values represent a surrogate for left ventricular stress [<125pg/ml normal, while above 350pg/ml high and potentially consistent with heart failure]	baseline and on-drug study end; 16, 20 or 24 weeks depending on study duration]
Primary	Percent change in epistaxis duration in minutes	A daily electronic record of each bleed, with start and end time, provides the daily epistaxis duration, compounded over each 3 weeks of study time	Summed minutes of bleeding at baseline 3 weeks and the last 3 weeks of dosing, over16-24 weeks of dosing
Secondary	Percent change in average gushing frequency	Patient rated intensity of each bleed, as in 0 or 1, averaged over 3 wk periods.	Last 3 weeks of drug period vs baseline 3 weeks; over 16-24 weeks of dosing
Secondary	Percent change in average bleed frequency	Annotated number of bleeds per day, and summed over 3 week periods	Last 3 weeks compared to the baseline 3 weeks; over 16-24 weeks of dosing
Secondary	Absolute [gm/dl] change in serum hemoglobin	Serum values drawn every 3 weeks	comparing last 6 weeks to baseline 3-6 weeks; over 16-24 weeks of drug dosing
Secondary	Change in the frequency of blood transfusions	Use of packed red blood cells over 6 week time periods.	Final 6 weeks of study, compared to baseline 3-6 weeks; over 16- 24 weeks of dosing
Secondary	Change in the frequency of IV iron infusions	Number of interval IV iron infusions in 6 week periods	Last 6 weeks of dosing to first 6 weeks; over 16-24 weeks of drug administration
Secondary	Percent change in the per bleed average epistaxis severity	Epistaxis severity score [0-10] housed in the current patient reported outcome instrument will be averaged	The final 3 weeks to the baseline 3 weeks of the study; for a16-24 week duration study
Secondary	Daily monitoring for change in systolic blood pressure [mm mercury] using daily recordings	Patients rising above 140 mm mercury, or those who increase by 20 or more mm mercury will trigger protocol defined treatments.	Daily from baseline through up to 24 weeks till on-drug study completion.
Secondary	Daily monitoring for change in diastolic blood pressure [mm mercury]	Patients rising above 90 mm mercury, or those who increase by 10 mm mercury or more will trigger protocol defined treatments.	Daily from baseline through up to 24 weeks till on-drug study completion
Secondary	Number of participants with changes in alanine aminotransferase [liver function test]	measurement every 3 weeks to evaluate fold increase with use of drug	Baseline and throughout the 16-24 week dosing period
Secondary	Monitor for active and safe trough serum drug concentrations	Assays to be analyzed to evaluate the exposures done to remain within safe and effective range [1ug/ ml to 10ug/ml].....	Over 16-24 week duration of study; once at steady state for each administered dose
Secondary	Evaluate for change in composite mental quality of life scores	short form health survey 36 [range 1-100, higher number representing better self-reported mental health]	baseline, week 12 and at study drug-dosing end; 16, 20 or 24weeks
Secondary	Evaluate for change in composite physical quality of life scores	short form health survey 36 [range 1-100, higher number representing better self-reported physical health]	baseline, week 12 and at study drug-dosing end; up to 24 weeks.
Secondary	Evaluate for change in fatigue composite scores	Patient-report outcome measurement information system-fatigue; [0-100 scale; lower number representing less fatigue]. Queries the degree of fatigue and the implications on physical functioning. Reduction of 5 or more in the composite score represents clinically relevant reductions in fatigue.	baseline and study end; up to 24 weeks